Cambridge Antibody Technology Grants License to Wyeth

12-Feb-2004

Cambridge Antibody Technology announces that Wyeth has exercised an option to license CAT's proprietary antibody phage display libraries for in-house use. The libraries will support Wyeth's activities in therapeutic antibody drug discovery and development across a broad range of therapeutic areas. This option to license CAT's libraries was granted to Wyeth as part of the collaboration agreement entered into in March 1999.

In return for Wyeth's exercise of the option, CAT will receive an upfront License fee. Wyeth has a number of exclusive therapeutic and diagnostic antibody product options related to its use of the library which, if exercised, will result in CAT receiving a product License fee and potential milestone and royalty payments.

Peter Chambre, Chief Executive Officer of CAT, commented "We have developed an excellent relationship with Wyeth over the past four years that has already resulted in Wyeth taking two exclusive product licences to human antibodies identified through work carried out at CAT in collaboration with Wyeth. This collaboration has clearly demonstrated the value of our platform technology and we are pleased that Wyeth has chosen to take this technology in-house."

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous